Clinical and Experimental Cardiology, Professor, Department in Chief, East Boston Hospital, Massachusetts, U.S.A
*Corresponding Author: FR Breijo-Marquez, Clinical and Experimental Cardiology, Professor, Department in Chief, East Boston Hospital, Massachusetts, U.S.A.
Received: November 08, 2022; Published: November 21, 2022
Spain is one of the few countries in Europe that still prescribes Acenocoumarol, similar to warfarin. So much so that primary care physicians are not allowed to prescribe other anticoagulants that are more effective and less bothersome for the patient when taking the digital INR test. The study was performed in a primary care health system and secondary category hospitals. We were setting in a population of 250 inhabitants in southeastern Spain (Number of patients to be treated is sufficient) with non-valvular atrial fibrillation and Acenocoumarol takers. The follow-up time was 12 months.
The statistical study was limited to an "observational/descriptive" study, taking into account the variations and lability of the INR value (International Normalized Ratio), whose figures universally considered – regardless of the type of cardiovascular pathology – have been proposed to be between 2-3, in a maximum term of one determination every 28 days, regardless of the figures obtained concerning previous ones. Given that the vast majority of Acenocoumarol intake occurs in elderly patients – over 65 years of age – and that these individuals are usually subject to a polymedication regimen, the medications taken by each of them were a fundamental reason for the assessment.
As fundamental conclusions in this clinical study, we must say that:
In time between INR determination and last intake of food and medication are not being correct; they tend to be anarchic INR determinations and when it is most convenient; research regarding drugs taken concomitantly with Acenocoumarol practically does not exist.
Keywords: Acenocoumarol; Spain; Atrial Fibrillation
Citation: FR Breijo-Marquez. “Misuse of the Drug Acenocoumarol in a Population of 250 Inhabitants with Non-valvular Atrial Fibrillation Assessed in a Region of Southeaster of Spain”.Acta Scientific Medical Sciences 6.12 (2022): 44-48.
Copyright: © 2022 FR Breijo-Marquez. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.